|
|
|
|
Cervical Cancer News Headlines
|
|
|
|
|
|
|
All Recent Cervical Cancer News Headlines |
|
|
|
|
Update on HPV study in Africa
Dr. Jennifer Young and Dr. Gweneth Lazenby traveled to
Arusha, Tanzania May 31st - June 19th for the purpose of
completing an on-going study on Human Papillomavirus (HPV) as part of a
research team from the University of Virginia Cancer Center in Charlottesville,
Virginia. HPV is a virus which causes cervical, anal, and oral cancers.
The team saw a total of 324 women in a 10 day period at
Selian Lutheran Hospital outside of Arusha. Most patients were from rural areas surrounding Arusha, a
largely Masai tribal population. These
African women were seeking screening for cervical cancer, which is not
routinely available due to costs and lack of skilled technicians. The research
team studied a rapid HPV test, which may replace pap smears for cervical cancer
screening in ......
POSTED 08/31/2010 at 04:07 PM --
|
Is the cervical cancer vaccine good to go?
VACCINE DEBATE:The arguments for and against the cervical cancer vaccination programme (Source: The Irish Times - Health)...
POSTED 08/30/2010 at 06:32 PM --
|
Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test
Authors: D C Rijkaart, V M H Coupe, F J van Kemenade, D A M Heideman, A T Hesselink, W Verweij, L Rozendaal, R H Verheijen, P J Snijders, J Berkhof
& C J L M Meijer (Source: British Journal of Cancer AOP)...
POSTED 08/30/2010 at 06:00 PM --
|
Predictors of Breast and Cervical Cancer Screening in a Spanish Metropolitan Area
Journal of Women's Health , Vol. 0, No. 0. (Source: Journal of Women)...
POSTED 08/30/2010 at 06:03 AM --
|
Treatment of genital warts: Facts and controversies
Abstract: There are two opposing approaches in the treatment of genital warts: (1) the traditional approach advocates complete elimination of all lesions, and (2) a second approach regards condyloma as merely a cosmetic nuisance. After a long journey through many arguments and scientific papers, we have concluded that many unknowns, uncertainties, and controversies concerning the value of treatment of genital warts in terms of clearing and curing the disease (ie, eradicating the viruses, preventing cancer, and reducing infectivity). There is no consensus at present of whether treatment of men with evidence of genital human papillomavirus infection influences the natural history of their female sex partner's cervical disease. (Source: Clinics in Dermatology)...
POSTED 08/28/2010 at 12:43 AM --
|
Namibia: September Cervical Cancer Month
September is the cervical cancer awareness month on the Cancer Association of Namibia calendar and in an effort to disseminate information about the disease, the Cancer Association of Namibia will on 4 September host the Pink Cup Cake Day as from 09:00. (Source: AllAfrica News: Health and Medicine)...
POSTED 08/27/2010 at 10:41 AM --
|
Boston Globe Editorial Calls Attention To Unnecessary Pap Tests
Even though an annual Pap test "is a long-standing, if much-dreaded, tradition" for many women, "a high proportion of these tests are unnecessary," according to a Boston Globe editorial. The editorial notes that "[g]uidelines recommend testing every two to three years for women at low risk of cervical cancer," such as women older than age 30 who have had multiple negative tests. According to the editorial, "Once a woman has had several negative tests in a row, the evidence strongly suggests that screening more often than recommended is of little benefit... (Source: Health News from Medical News Today)...
POSTED 08/27/2010 at 05:00 AM --
|
Feasibility and Safety of a New Robotic Thyroidectomy through a Gasless, Transaxillary Single-Incision Approach
In the late 20th century, surgeons became concerned about patient satisfaction factors, eg, incision scars, pain, and time to return to work after surgery. Consequently, minimally invasive techniques, such as endoscopy and laparoscopic surgery, were developed. These trends also influenced thyroid surgery and the development of new techniques, such as minimally invasive open thyroidectomy and endoscopic thyroidectomy. Since endoscopic subtotal parathyroidectomy was first introduced by Ganger in 1996 and endoscopic thyroidectomy by Hüscher in 1997, various types of endoscopic thyroid operations have been devised using axillary, breast, anterior chest, and cervical approaches. In addition, development of robotic surgical systems has encouraged many surgeons to incorporate more dexterous surg......
POSTED 08/27/2010 at 03:04 AM --
|
Inhibitory effects on nuclear factor κB of the Vietnamese freshwater cyanobacteria
Abstract Several Vietnamese freshwater cyanobacteria were collected and evaluated for their effects on the transcriptional nuclear
factor κB (NF-κB) which are involving in the cancer and inflammatory diseases. Five extraction conditions were tested and
a solution of 2% acetic acid in methanol provided highest yield of extract from bacterial biomass. The Microcystis aeruginosa TC-1 and TC-3 strains showed strong NF-κB inhibitory activity with IC50 values of 6.1 and 5.3 μg/ml, respectively. Moreover, all tested cyanobacteria exhibited cytotoxicity on human cervical cancer
HeLa cells in a dose-dependent manner. Ergosterol (1) isolated from M. aeruginosa TC-3 strains strongly inhibited NF-κB activation with IC50 values of 0.91 μg/ml.
Content Type Journal Arti......
POSTED 08/26/2010 at 01:17 PM --
|
Outcomes from a mass media campaign to promote cervical screening in NSW, Australia
Conclusions
Despite the ecological nature of this study, the mass media campaign appears to have been successful in increasing screening in unscreened and underscreened women in NSW. (Source: Journal of Epidemiology and Community Health)...
POSTED 08/26/2010 at 07:54 AM --
|
National Cancer Institute Funds Second Year Of Grant To Guided Therapeutics To Commercialize Non-invasive Cervical Cancer Detection Device
Guided Therapeutics, Inc. (GT) (OTCBB: GTHP) announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009. The three-year grant provides additional resources to commercialize and bring to market the LightTouch⢠non-invasive cervical cancer detection device and single-patient-use disposable... (Source: Health News from Medical News Today)...
POSTED 08/26/2010 at 07:00 AM --
|
Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV
In this study, we compared the effects of SKI-606 with Iressa, Src/Abl and EGF-R kinase inhibitors, respectively, on selected parameters in HeLa and SiHa cervical cancer cell lines, which express E6/E7 oncoproteins of high-risk HPV types 18 and 16, respectively. Our results show that SKI-606 and Iressa inhibit cell proliferation and provoke G0-G1 cell cycle arrest and reduction of S and G2-M phase using 2 and 5 μM concentrations of these inhibitors. In contrast, SKI-606 induces differentiation to an epithelial phenotype “mesenchymal-epithelial transition”; thus SKI-606 causes a dramatic decrease in cell motility and invasion abilities of HeLa and SiHa cancer cells, in comparison to untreated cells and Iressa-treated cells in which these parameters are only slightl......
POSTED 08/26/2010 at 12:24 AM --
|
Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women.
The objective of this study was to identify whether polymorphic variants of p53 at codon 72 and p21 at codon 31 were associated with increased risk for cervical cancer, either independently or jointly, among Chinese women from southern Han. We genotyped p53 codon 72 and p21 codon 31 polymorphisms of peripheral blood DNA from 104 cervical cancer patients and 160 controls. Genotyping was confirmed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct DNA sequencing. We observed an increased risk of cervical cancer associated with the p53 Arg/Arg (OR, 2.25; 95% CI, 1.11-4.54) or p21 Ser/Ser (OR, 2.09; 95% CI, 1.04-4.19) genotype, compared with the p53 Pro/Pro or p21 Arg/Arg genotype, respectively. In additional, interaction between these p53 and p21 polym......
POSTED 08/25/2010 at 09:54 AM --
|
GSK European Commission Amends Licence For Cervarix®
GlaxoSmithKline (GSK) confirmed that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. The approval from the European Commission is important as it recognises the extent of cervical cancer protection demonstrated by Cervarix®, which was not highlighted by the previous indication... (Source: Health News from Medical News Today)...
POSTED 08/25/2010 at 07:00 AM --
|
New ACOG Recommendations On HPV Vaccination Mirror Government Guidelines
On Monday, the American College of Obstetricians and Gynecologists released recommendations that girls should be vaccinated against the human papillomavirus at ages 11 or 12, Reuters reports. The recommendations, published in the journal Obstetrics & Gynecology, back government guidelines on HPV vaccination. Persistent HPV infection is the leading cause of cervical cancer, and it also can lead to anal and penile cancer. Like the government guidelines, ACOG recommended HPV vaccination for girls before they become sexually active... (Source: Health News from Medical News Today)...
POSTED 08/25/2010 at 07:00 AM --
|
EC approves amended marketing authorisation for Cervarix to include more human papillomavirus strains
Source: PharmaTimes
Area: News
According to a report by PharmaTimes, the European Commission has approved an amendment to the licence of Cervarix to better reflect the scope of protection it offers. The marketing authorisation for the vaccine has therefore been adjusted to show that its efficacy goes beyond the human papilloma virus strains (HPV) 16 and 18 to provide protection against 80% of all cervical cancers.
The amendment is based on data from the PATRICIA study that demonstrated Cervarix is effective against HPV strains 16, 18, 31, 33 and 45, which was not highlighted in its original indication. (Source: NeLM - News)...
POSTED 08/24/2010 at 06:00 PM --
|
Ob-Gyns Recommend HPV Vaccination For Young Girls
Girls ages 11 to 12 should receive either of the two FDA-approved vaccines to prevent cervical cancer, ideally before they become sexually active, according to The American College of Obstetricians and Gynecologists. In its recommendations issued today, The College emphasizes that routine Pap screening is still necessary for all women beginning at age 21, including those who have had the cervical cancer vaccine. Cervical cancer is caused by HPV, a sexually transmitted viral infection... (Source: Health News from Medical News Today)...
POSTED 08/24/2010 at 05:00 AM --
|
GSK European Commission amends licence for Cervarix®
GlaxoSmithKline (GSK) confirmed today that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. (Source: GSK news)...
POSTED 08/24/2010 at 05:00 AM --
|
Cervical cancer campaign launched
A leafleting campaign in Scotland has been launched to encourage more women to have cervical screening tests (Source: Nursing in Practice)...
POSTED 08/24/2010 at 02:04 AM --
|
The Society For Adolescent Health And Medicine (SAHM) Advocates For Ways To Improve Immunization Rates And Halt Disease Outbreaks
In light of today's report of the National Immunization Survey results, the Society for Adolescent Health and Medicine (SAHM) encourages increased efforts in fully immunizing all adolescents. The report issued by the National Immunization Survey (NIS) shows progress in increasing immunization rates among teens 13-17 years of age. However, rates remain unacceptably low for those vaccines that are targeted specifically to prevent disease in adolescents: meningococcal meningitis (53.6 %), human papillomavirus (44.3% received one dose, while only 26... (Source: Health News from Medical News Today)...
POSTED 08/24/2010 at 02:00 AM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Arthrit-Eze |
|
Arthrit-Eze is the most advanced
formula on the market today |
|
It offers potential relief and
rejuvenation for all forms of arthritis, safely, naturally and without side
effects!
NO PRESCRIPTION REQUIRED! |
|
CLICK HERE
for more info... |
|
|
